Novartis Foundation

Novartis Foundation and Partners Launch New Hypertension Program in Ghana

Community-based Hypertension Improvement Project (ComHIP) is an innovative healthcare model designed to improve hypertension management and control
Press Release
  • Community-based Hypertension Improvement Project (ComHIP) is an innovative healthcare model designed to improve hypertension management and control
     
  • Screening and treatment is shifted to the community and technology supports healthcare workers and empowers patient self-management
     
  • More than one quarter of the adult population in Ghana has hypertension, but only 4% of these hypertensive patients have it under control
     

Novartis Launches ‘Novartis Access’, a Portfolio of Affordable Medicines to Treat Chronic Diseases in Lower-income Countries

First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer
Summary: 
  • First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer
  • Novartis portfolio to be offered to governments and non-governmental organizations in low- and low-middle-income countries for USD 1 per treatment, per month
  • Some 28 million people die from chronic diseases in low- and middle-income countries each year, representing 75% of such deaths globally1
Press Release
  • First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer
  • Novartis portfolio to be offered to governments and non-governmental organizations in low- and low-middle-income countries for USD 1 per treatment, per month
  • Some 28 million people die from chronic diseases in low- and middle-income countries each year, representing 75% of such deaths globally1

Novartis Continues Commitment to go the Last Mile in Effort to Eliminate Leprosy

New five-year commitment includes donation of treatments worth more than USD 40 million and is expected to reach an estimated 1.3 million patients
Summary: 

Novartis continues commitment to go the last mile in effort to eliminate leprosy

  • New five-year commitment includes donation of treatments worth more than USD 40 million and is expected to reach an estimated 1.3 million patients
     
  • Novartis Foundation’s new leprosy contact tracing program now launched in five countries
     
  • The company and foundation have a strong legacy in the fight against leprosy, donating medicines and developing programs to improve care of patients
Press Release

Novartis continues commitment to go the last mile in effort to eliminate leprosy

  • New five-year commitment includes donation of treatments worth more than USD 40 million and is expected to reach an estimated 1.3 million patients
     
  • Novartis Foundation’s new leprosy contact tracing program now launched in five countries
     
  • The company and foundation have a strong legacy in the fight against leprosy, donating medicines and developing programs to improve care of patients

Novartis Foundation Confirms New Members of its Board of Trustees, Including New Chairman Dr. Joerg Reinhardt

Summary: 
  • Dr. Joerg Reinhardt, Chairman of the Novartis Board of Directors, will serve as Chairman of the Foundation Board of trustees
     
  • New trustees also include Professor Peter Piot of the London School of Hygiene & Tropical Medicine, Dr. Rebecca Weintraub of Harvard Medical School, and Mr. Rainer Boehm from Novartis Pharmaceuticals
     
  • The Novartis Foundation and its partners are pioneering innovative healthcare models to have a transformational impact on the health of the poorest populations
Press Release
  • Dr. Joerg Reinhardt, Chairman of the Novartis Board of Directors, will serve as Chairman of the Foundation Board of trustees
     
  • New trustees also include Professor Peter Piot of the London School of Hygiene & Tropical Medicine, Dr. Rebecca Weintraub of Harvard Medical School, and Mr. Rainer Boehm from Novartis Pharmaceuticals
     
  • The Novartis Foundation and its partners are pioneering innovative healthcare models to have a transformational impact on the health of the poorest populations

Pages

Subscribe to Novartis Foundation